Immunotherapy and vaccine before surgery for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of immunotherapy (a drug that helps your immune system fight cancer) and a mitochondrial vaccine given before surgery for head and neck squamous cell carcinoma. The goal is to help reduce cancer recurrence and improve survival after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head and neck squamous cell carcinoma (a type of cancer in the mouth, throat, or related areas) that has not spread to the nasopharynx (top of the throat behind the nose)
- Your cancer is stage II–IVB and your doctors believe it can be completely removed by surgery
- Your cancer cells show positive expression of IMP3 protein (a marker found in lab tests)
- You are able to undergo major surgery to remove the cancer
- Your blood counts, liver, kidney, and heart function are adequate for this treatment
- You have not received prior immunotherapy drugs (PD-1, PD-L1, CTLA-4 inhibitors) or other anti-cancer vaccines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy along with chemotherapy before surgery can help treat locally advanced head and neck cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This trial tests whether combining two immunotherapy drugs before surgery is better than one alone for advanced head and neck cancer. The goal is to see if the combination can shrink tumors more and improve outcomes.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
This study tests whether giving a combination of immunotherapy (camrelizumab) with either an EGFR antibody or chemotherapy before and after surgery can help treat locally advanced head and neck cancer. It aims to see if this approach improves outcomes compared to standard care.
This trial tests a new immunotherapy drug (adelbelimab) combined with chemotherapy given before surgery, for people with head and neck cancer. The goal is to see if this combination can shrink the tumor and improve the chances of successful surgery.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.